<DOC>
	<DOCNO>NCT00903981</DOCNO>
	<brief_summary>The purpose study confirm efficacy safety Avanafil 100mg , 200mg placebo administer orally 12 week patient erectile dysfunction . The efficacy evaluate IIEF , SEP Q2 Q3 GEAQ safety evaluate laboratory test , vital sign , physical examination adverse event .</brief_summary>
	<brief_title>Therapeutic Confirmatory Study Evaluate Efficacy Safety Avanafil</brief_title>
	<detailed_description />
	<mesh_term>Erectile Dysfunction</mesh_term>
	<criteria>male subject age 19 70 history erectile dysfunction least 6 month subject stable monogamous relationship partner free pregnancy lactation well prevent conception subject consent participate clinical study write subject attempt sexual intercourse least 4 time separate day 4 week ' free runin period , failure rate 50 % history spinal cord injury radical prostatectomy subject whose penis anatomically deform erectile dysfunction due neurogenic endocrine cause subject uncontrolled major psychiatric disorder accept therapy significant neurological abnormality history cancer chemotherapy within 1 year subject addict alcohol continuously misuse dependent drug subject hepatic dysfunction ( GOP , GPT â‰¥ 3xUNL ) renal dysfunction ( serum creatinine &gt; 2.0 ) subject uncontrollable diabetes ( FPG &gt; 180 ) subject sho proliferative diabetic retinopathy history stroke , transient ischemic attack , myocardial infarction , heart failure need medically treat , unstable angina fatal arrhythmia coronary artery bypass graft within 6 month serious hypotension uncontrollable severe hypertension hematological disorder likely develop priapism sickle cell disease , multiple myeloma , leukemia subject retinitis pigmentosa subject suffer serious GI bleeding disorder within 1 year subject take PDE5 inhibitor ED therapy within 2 week subject use nonconcomitant medication ( Nitrate/NO donor , Androgens , antiandrogen , trazodone , Anticoagulant , overthecounter drug know inhibit activity CYP3A4 ) history hypersensitivity PDE5 inhibitor respond subject hypoactive sexual desire subject intention sexual intercourse 4 time separate day 4 week ' free runin period subject take investigational product within 30 day clinical study subject judge unsuitable clinical study reason</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2009</verification_date>
</DOC>